Allen Mooney & Barnes Investment Advisors LLC Buys 17,835 Shares of Kenvue Inc. (NYSE:KVUE)

Allen Mooney & Barnes Investment Advisors LLC boosted its stake in Kenvue Inc. (NYSE:KVUE) by 3.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 564,498 shares of the company’s stock after purchasing an additional 17,835 shares during the quarter. Kenvue comprises approximately 2.2% of Allen Mooney & Barnes Investment Advisors LLC’s portfolio, making the stock its 13th biggest holding. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Kenvue were worth $13,537,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares in the last quarter. Vanguard Group Inc. lifted its position in Kenvue by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after buying an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Kenvue by 12.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock worth $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company’s stock worth $980,989,000 after acquiring an additional 1,391,854 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in Kenvue by 61.5% during the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after buying an additional 16,269,721 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on KVUE. Evercore ISI began coverage on Kenvue in a research note on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target on the stock. Redburn Atlantic started coverage on Kenvue in a research report on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price objective on the stock. Citigroup boosted their target price on Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a research note on Friday, May 9th. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Finally, Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $25.33.

Kenvue Price Performance

KVUE stock opened at $21.85 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a 50 day moving average price of $23.02 and a 200-day moving average price of $22.54. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $25.17. The firm has a market capitalization of $41.91 billion, a price-to-earnings ratio of 41.22, a PEG ratio of 2.62 and a beta of 0.98.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter last year, the company earned $0.28 EPS. The firm’s revenue for the quarter was down 3.9% on a year-over-year basis. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.75%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue’s dividend payout ratio is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.